Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma

References

• González-Vela MC, Val-Bernal JF, González-López MA, Novell M, Fernandez-Llaca H. Collision of pigmented benign tumours: a possible simulator of melanoma. Acta Derm Venereol. 2008;88:92–93. doi:10.2340/00015555-0334.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e10. doi:10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Bathia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology. 2009;23:488–4962.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo KA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, Lu L-S, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, et al. Preclinical development of ipilimumab and nivolumab comination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11(9):e0161779. doi:10.1371/journal.pone.0161779.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber W-J, et al. Checkpoint blockage of cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577–581. doi:10.1038/nature13988.
   PubMed Web of Science ®Google Scholar
• Wood LM, Guirnalda PD, Seavey MM, Paterson Y. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol. Res.. 2008;42:233–245. doi:10.1007/s12026-008-8087-0.
   PubMed Web of Science ®Google Scholar
• Terán-Navarro H, Calderon-Gonzalez R, Salcines-Cuevas D, Garcia I, Marradi M, Freire J, Salmon E, Portillo-Gonzalez M, Frande-Cabanes E, García-Castaño A., et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 2015; 33(12):1325–1333.
   Google Scholar
• Sacco J, Evans M, Harrington KJ, Man S, Powell N, Shaw RJ, Jones TM. Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001. Hum Vaccin Immunother. 2016;12:1085–1086. doi:10.1080/21645515.2015.1121338.
   PubMed Web of Science ®Google Scholar
• Sun R, Liu Y. Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines. Hum Vaccin Immunother. 2013;9:1058–1068. doi:10.4161/hv.23871.
   PubMed Web of Science ®Google Scholar
• Carrero JA, Vivanco-Cid H, Unanue ER. Listeriolysin o is strongly immunogenic independently of its cytotoxic activity. PLoS One. 2012;7(3):e32310. doi:10.1371/journal.pone.0032310.
   PubMed Web of Science ®Google Scholar
• Bronchalo-Vicente L, Rodriguez-Del Rio E, Freire J, Calderon-Gonzalez R, Frande-Cabanes E, Gomez-Roman JJ, Fernández-Llaca H, Yañez-Diaz S, Alvarez-Dominguez C, Chakravortty D. A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes. PLoS One. 2015;10(3):e0117923. doi:10.1371/journal.pone.0117923.
   PubMed Web of Science ®Google Scholar
• Wood LM, Peterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumour immunotherapy. Front Cell Infect Microbiol. 2014;4:51. doi:10.3389/fcimb.2014.00051.
   PubMed Web of Science ®Google Scholar
• Calderon-Gonzalez R, Bronchalo-Vicente L, Freire J, Frande-Cabanes E, Alaez-Alvarez L, Gomez-Roman J, Yañez-Diaz S, Alvarez-Dominguez C. Exceptional anti-neoplastic activity of a dendritic-cell-targetted vaccine loaded with a Listeria peptide proposed against metastatic melanoma. Oncotarget. 2016;7(13):16855–16865. doi:10.18632/oncotarget.7806.
   PubMed Web of Science ®Google Scholar
• Calderon-Gonzalez R, Terán-Navarro H, García I, Marradi M, Salcines-Cuevas D, Yañez-Diaz S, Solis-Angulo A, Frande-Cabanes E, Fariñas MC, Garcia-Castaño A, et al. Gold glyconanoparticles coupled to listeriolysin O peptide 91-99 serve as adjuvant therapy for solid tumours. Nanoscale. 2017;9(30):10721–10731. doi:10.1039/c7nr02494k.
   PubMed Web of Science ®Google Scholar
• Marradi M, Chiodo F, Garcia I, Penadés S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem Soc Rev. 2016;42:4728–4745. doi:10.1039/c2cs35420a.
   Google Scholar
• Rojo J, Díaz V, de la Fuente JM, Segura I, Barrientos AG, Riese HH, Bernad A, Penadés S. Gold glyconanoparticles as new tools in antiadhesive therapy. Chembiochem. 2004;5(3):291–297. doi:10.1002/cbic.200300726.
   PubMed Web of Science ®Google Scholar
• Brinas RP, Sundgren A, Sahoo P, Morey S, Rittenhouse-Olson K, Wilding GE, Deng W, Barchi JJ. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. J Bioconjugate Chem. 2012;23:1513–1523. doi:10.1021/bc200606s.
   PubMed Web of Science ®Google Scholar
• Parry AL, Clemson NA, Ellis J, Bernhard SSR, Davis BG, Cameron NR. Multicopy multivalent’ glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines. J Am Chem Soc. 2013;135:9362–9365. doi:10.1021/ja4046857.
   PubMed Web of Science ®Google Scholar
• Ojeda R, de Paz JL, Barrientos AG, Martín-Lomas M, Penadés S. Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines. Carbohydr Res. 2007;342(3–4):448–459. doi:10.1016/j.carres.2006.11.018.
   PubMed Web of Science ®Google Scholar
• Safari D, Marradi M, Chiodo F, Th Dekker HA, Shan Y, Adamo R, Oscarson S, Rijkers GT, Lahmann M, Kamerling JP, et al. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. Nanomedicine. 2012;7:651–662. doi:10.2217/nnm.11.151.
   PubMed Web of Science ®Google Scholar
• Gregory AE, Judy BM, Qazi O, Blumentritt CA, Brown KA, Shaw AM, Torres AG, Titball RW. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomed-Nanotechnol. 2015;11(2):447–456. doi:10.1016/j.nano.2014.08.005.
   PubMed Web of Science ®Google Scholar
• Vetro M, Safari D, Fallarini S, Salsabila K, Lahmann M, Penades S, Lay L, Marradi M, Compostella D. Preparation and immunogeniticity of gold glyconanoparticles as anti-pneumococcal vaccine model. Nanomedicine (Lond). 2017;12(1):13–23. doi:10.2217/nnm-2016-0306.
   PubMed Web of Science ®Google Scholar
• Martínez-Ávila O, Hijazi K, Marradi M, Clavel C, Campion C, Kelly C, Penadés S. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chem Eur J. 2009;15:9874–9888. doi:10.1002/chem.v15:38.
   PubMed Web of Science ®Google Scholar
• Martinez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcami J, Penades S. Multivalent mano-glyconanoparticles inhibit DC-SIGN mediated HIV-1 trans-infection of human T cells. Chembiochem. 2009;10:1806–1809. doi:10.1002/cbic.200900294.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Del Rio E, Marradi M, Calderon-Gonzalez R, Frande-Cabanes E, Penadés S, Petrovsky N, Alvarez-Dominguez C. A gold-glyconanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against Listeria infection. Vaccine. 2015;33:1465–1473. doi:10.1016/j.vaccine.2015.01.062.
   PubMed Web of Science ®Google Scholar
• Calderon-Gonzalez R, Terán-Navarro H, Frande-Cabanes E, Ferrández-Fernández E, Freire J, Penadés S, Marradi M, García I, Gomez-Román J, Yañez-Díaz S, et al. Pregnancy vaccination with gold glyconanoparticles carrying Listeria monocytogenes peptides protects against listeriosis and brain and cutaneous associated morbidities. Nanomaterials. 2016;6:521. nano6080151. doi:10.3390/nano6080151.
   Web of Science ®Google Scholar
• Calderon-Gonzalez R, Frande-Cabanes E, Teran-Navarro H, Marimon JM, Freire J, Salcines-Cuevas D, Carmen Fariñas M, Onzalez-Rico C, Marradi M, Garcia I, et al. GNP-GAPDH1-22 nanovaccines prevent neonatal listeriosis by blocking microglial apoptosis and bacterial dissemination.. Oncotarget. 2017;8(33):53916–53934. doi:10.18632/oncotarget.19405.
   PubMedGoogle Scholar
• Chandra D, Selvanesan BC, Yuan Z, Libutti SK, Koba W, Beck A, Zhu K, Casadevall A, Dadachova E, Gravekamp C. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. 2017;8(13):20729–20740. doi:10.18632/oncotarget.15117.
   PubMed Web of Science ®Google Scholar
• Kim SH, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009;69:5860–5866. doi:10.1158/0008-5472.CAN-08-3660.
   PubMed Web of Science ®Google Scholar
• Calderon-Gonzalez R, Teran-Navarro H, Marimon JM, González-Rico C, Calvo-Montes J, Frande-Cabanes E, Alkorta-Gurrutxaga M, Fariñas MC, Martínez-Martínez L, Perez-Trallero E, et al. Biomarker tools to design clinical vaccines determined from a study of annual listeriosis incidence in northern Spain. Front Immunol. 2016;7:541. doi:10.3389/fimmu.2016.00541.
   PubMed Web of Science ®Google Scholar
• European Food Safety Authority (EFSA). The European Union Summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2016. EFSA Journal. 2017;15(12):5077.
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Trans Med. 2005;3:1–10. doi:10.1186/1479-5876-3-4.
   PubMed Web of Science ®Google Scholar
• Oshita C, Wu M-N, Guo X-F, Zhang S-H, Miao Q-F, Zhen Y-S. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep. 2012;28:1131–1138. doi:10.3892/or.2012.1910.
   PubMed Web of Science ®Google Scholar
• de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato A, Ancarani V, et al. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study. J Transl Med. 2014;12:209. doi:10.1186/1479-5876-12-209.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix formula. Cancer Immunol Immunother. 2014;63(9):959–967. doi:10.1007/s00262-014-1558-3.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gurpide A, Prieto J, Pardo J, Berraondo P, et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 2013;73:139–149. doi:10.1158/0008-5472.CAN-12-2660.
   PubMed Web of Science ®Google Scholar
• Edelson BT, Bradstreet TR, Hildner K, Carrero JA, Frederick KE, Wumesh KC, Belizaire R, Aoshi T, Schreiber RD, Miller MJ, et al. CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity. 2011;35(2):236–248. doi:10.1016/j.immuni.2011.06.012.
   PubMed Web of Science ®Google Scholar
• Diamont MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumours. J Exp Med. 2011;208:1989–2003. doi:10.1084/jem.20101158.
   PubMed Web of Science ®Google Scholar
• Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322:1097–1100. doi:10.1126/science.1164206.
   PubMed Web of Science ®Google Scholar
• Lauerova L, Dusek L, Simickova M, Kocák I, Vagundová M, Zaloudík J, Kovarík J. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma. 2002;49(3):159–166.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541. doi:10.1038/s41418-017-0012-4.
   Google Scholar
• Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013;19:6151–6162. doi:10.1158/1078-0432.CCR-13-1189.
   PubMed Web of Science ®Google Scholar
• Budczies J, Bockmayr M, Klauschen F, Endris V, Fröhling S, Schirmacher P, Denkert C, Stenzinger A. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes Cancer. 2017 Aug;56(8):651–659. doi:10.1002/gcc.22468.
   PubMed Web of Science ®Google Scholar
• Homet-Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, et al. Response to programmed cell death-1 blockade in a murine melanoma syngenic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol Res. 2016;4(10):845–857. doi:10.1158/2326-6066.CIR-16-0060.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer Immunology. The “cancer immunogram”. Science. 2016;352(6286):658–660. doi:10.1126/science.aaf2834.
   PubMed Web of Science ®Google Scholar
• Dubensky TW, Kanne DB, Leong ML. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines. 2013;1:131–143. doi:10.1177/2051013613501988.
   PubMedGoogle Scholar
• Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockage. Sci Transl Med. 2015;7(283):283ra52. doi:10.1126/scitranslmed.aad3106.
   PubMed Web of Science ®Google Scholar
• Aris M, Bravo AI, Barrio MM, Mordoh J. Inoculation site from a cutaneous melanoma patient treated with an allogenic therapeutic vaccine: a case report. Front Immunol. 2015;6:144. doi:10.3389/fimmu.2015.00144.
   PubMed Web of Science ®Google Scholar
• Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol. 2015;6:46. doi:10.3389/fimmu.2015.00046.
   PubMed Web of Science ®Google Scholar